Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...

Introduction Long-term population-based safety studies, applying advanced causal inference techniques, including an active comparator with new-user design, are needed to investigate skin cancer ...

Dr. Carlos Correa discusses the impact of evergreening strategies on access to generic and biosimilar medicines globally.

We performed model sensitivity analyses to reveal potential therapeutic targets through an identification of processes critically affecting thymic function; we further explored differences in thymic ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires ...

After a 1-week break, this changes to a monthly injection. Fingolimod (Gilenya) is an oral capsule that you take once daily. It was the first oral medication approved by the FDA to treat RRMS.

The litigation revolves around US Patent No. 9,187,405, granted in 2015, which covers a dosing regimen for Gilenya (fingolimod) in relapsing-remitting MS. Gilenya is Novartis' third-biggest ...

为解决炎症性肠病（IBD）治疗难题，四川大学华西医院研究人员开展 S1PR1 相关研究，发现 SAR247799 可保护内皮屏障改善疾病。该研究为 IBD 等疾病治疗提供新策略，极具科研价值，推荐阅读。

Biomarkers of neurodegeneration and neuronal injury have the potential to improve diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy. Neurofilament proteins (NfPs) are ...